- Home
- BOSC vs FBIOP Comparison
BOSC vs FBIOP Comparison
Compare BOSC & FBIOP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOSC
- FBIOP
- Stock Information
- Founded
- BOSC 1990
- FBIOP N/A
- Country
- BOSC Israel
- FBIOP United States
- Employees
- BOSC N/A
- FBIOP 101
- Industry
- BOSC Computer Communications Equipment
- FBIOP Biotechnology: Pharmaceutical Preparations
- Sector
- BOSC Telecommunications
- FBIOP Health Care
- Exchange
- BOSC Nasdaq
- FBIOP Nasdaq
- Market Cap
- BOSC N/A
- FBIOP N/A
- IPO Year
- BOSC 1996
- FBIOP N/A
- Fundamental
- Price
- BOSC $4.52
- FBIOP $7.90
- Analyst Decision
- BOSC Strong Buy
- FBIOP
- Analyst Count
- BOSC 1
- FBIOP 0
- Target Price
- BOSC $5.00
- FBIOP N/A
- AVG Volume (30 Days)
- BOSC 428.9K
- FBIOP N/A
- Earning Date
- BOSC 05-29-2025
- FBIOP N/A
- Dividend Yield
- BOSC N/A
- FBIOP N/A
- EPS Growth
- BOSC 35.10
- FBIOP N/A
- EPS
- BOSC 0.49
- FBIOP N/A
- Revenue
- BOSC $43,688,000.00
- FBIOP N/A
- Revenue This Year
- BOSC N/A
- FBIOP N/A
- Revenue Next Year
- BOSC N/A
- FBIOP N/A
- P/E Ratio
- BOSC $9.29
- FBIOP N/A
- Revenue Growth
- BOSC 0.84
- FBIOP N/A
- 52 Week Low
- BOSC $2.50
- FBIOP N/A
- 52 Week High
- BOSC $5.50
- FBIOP N/A
- Technical
- Relative Strength Index (RSI)
- BOSC 70.17
- FBIOP 74.91
- Support Level
- BOSC $3.83
- FBIOP $6.43
- Resistance Level
- BOSC $5.50
- FBIOP $7.00
- Average True Range (ATR)
- BOSC 0.26
- FBIOP 0.39
- MACD
- BOSC 0.06
- FBIOP 0.09
- Stochastic Oscillator
- BOSC 47.59
- FBIOP 96.95
About FBIOP Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.